Shukra Pharmaceuticals Holds 33rd AGM on Sep 28, 2026, Approves Dividend
Shukra Pharmaceuticals Limited held its 33rd AGM on September 28, 2026. The meeting approved the final dividend for FY25-26 and re-appointed Ms. Sanskruti Patel as Director. Mr. Dinesh Chauhan's appointment as Independent Director was also regularized. Voting results will be announced within 48 hours.
The AGM is a significant corporate event where key decisions are made, including dividend declarations and director appointments. These decisions can impact shareholder value and company governance, thus having a medium impact.
The announcement details the proceedings of the Annual General Meeting, including the approval of routine corporate actions like dividend declaration and director re-appointments. While positive for shareholders receiving a dividend, the overall impact is neutral as it represents standard corporate governance.
Shukra Pharmaceuticals Limited conducted its 33rd Annual General Meeting (AGM) on Monday, September 28, 2026. The virtual meeting, held via video conferencing, commenced at 12:00 p.m. (IST) and concluded at 12:24 p.m. (IST).
The AGM proceedings included the consideration and adoption of the audited financial statements for the financial year ended March 31, 2026, along with the reports of the Board of Directors and Auditors. Key resolutions passed included the approval and declaration of a final dividend for the financial year 2025-26 and the re-appointment of Ms. Sanskruti Patel as a Director (Executive). Additionally, the regularization of the appointment of Mr. Dinesh Chauhan as an Independent Director was approved.
The meeting was chaired by Mr. Dhruvin Shah, Executive Director, with the Company Secretary, Mr. Shivkant Dhakad, facilitating the virtual proceedings. The company utilized services from National Securities Depository Limited (NSDL) for remote e-voting and voting during the AGM. The results of the voting are expected to be announced within 48 hours of the meeting's conclusion and will be displayed on the company's website and stock exchanges.
What to do with a filing like this
Shukra Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Shukra Pharmaceuticals Limited. Read the original for the full detail.